Ckd and HF expanded indications. That’s all.
several phase 2 products but half of those fail and even if they succeed , it takes years to get to market. Stiolto never going anywhere. Failed product. At some point spiriva is going generic. Same with Pradaxa. We can’t have everyone selling Empa. I have no clue what the future holds , but seems impossible to not have cuts sometime soon.
several phase 2 products but half of those fail and even if they succeed , it takes years to get to market. Stiolto never going anywhere. Failed product. At some point spiriva is going generic. Same with Pradaxa. We can’t have everyone selling Empa. I have no clue what the future holds , but seems impossible to not have cuts sometime soon.